Advances in pharmocogenetics of platinum neurotoxicity

Abstract

Abstract: Platinum-based drugs are widely used to treat lung cancer, colorectal cancer, ovarian cancer, breast cancer and other cancers. However, the efficacy of platinum drugs are often restricted due to many serious side effects, especially neurotoxicity. There is a large of interindividual variability in platinum-based drugs induced neurotoxicity. It is thought that drug metabolism-related genetic mutation is one of the important reasons. This review summarizes the relationship between the polymorphisms of genes encoding platinum-based drug transporters, platinum-based drug-metabolizing enzymes and DNA repair enzymes and neurotoxicity of platinum-based drugs.

Key words: Pharmacogenetics, Neurotoxicity, Platinum-based drugs

CLC Number:

R969.1

DENG Jian-hao^1,2, SHI Dao-hua². Advances in pharmocogenetics of platinum neurotoxicity[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(4): 458-462.

References

[1] Rosenberg B, VanCamp L, Trosko JE, et al. Platinum compounds: a new class of potent antitumour agents [J]. Nature, 1969, 222(5191): 385-386.
[2] Albers JW, Chaudhry V, Cavaletti G, et al. Interventions for preventing neuropathy caused by cisplatin and related compounds [J]. Cochrane Database Syst Rev, 2011(2): CD005228.
[3] Sul JK, Deangelis LM. Neurologic complications of cancer chemotherapy [J]. Semin Oncol, 2006, 33(3): 324-332.
[4] McKeage MJ, Hsu T, Screnci D, et al. Nucleolar damage correlates with neurotoxicity induced by different platinum drugs [J]. Br J Cancer, 2001, 85(8): 1219-1225.
[5] McDonald ES, Randon KR, Knight A, et al. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity [J]. Neurobiol Dis, 2005, 18(2): 305-313.
[6] Suk R, Gurubhagavatula S, Park S, et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients [J]. Clin Cancer Res, 2005, 11(4): 1534-1538.
[7] Arnesano F, Scintilla S, Natile G. Interaction between platinum complexes and a methionine motif found in copper transport proteins [J]. Angew Chem Int Ed Engl, 2007, 46(47): 9062-9064.
[8] Chen YC, Tzeng CH, Chen PM, et al. Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma [J]. Cancer Sci, 2010, 101(2): 530-535.
[9] Sheehan D, Meade G, Foley VM, et al. Structure, function and evolution of glutathione transferases: implications for classification of non-mammalian members of an ancient enzyme superfamily [J]. Biochem J, 2001, 360(Pt 1): 1-16.
[10] Ruzzo A, Graziano F, Loupakis F, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy [J]. J Clin Oncol, 2007, 25(10): 1247-1254.
[11] Lecomte T, Landi B, Beaune P, et al. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy [J]. Clin Cancer Res, 2006, 12(10): 3050-3056.
[12] Pillot GA, Read WL, Hennenfent KL, et al. A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report [J]. J Thorac Oncol, 2006, 1(9): 972-978.
[13] Khrunin AV, Moisseev A, Gorbunova V, et al. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients [J]. Pharmacogenomics J, 2010, 10(1): 54-61.
[14] Barahmani N, Carpentieri S, Li XN, et al. Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma [J]. Neuro Oncol, 2009, 11(3): 292-300.
[15] Ishida S, Lee J, Thiele DJ, et al. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals [J]. Proc Natl Acad Sci U S A, 2002, 99(22): 14298-14302.
[16] Liu JJ, Jamieson SM, Subramaniam J, et al. Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity [J]. Cancer Chemother Pharmacol, 2009, 64(4): 847-856.
[17] Safaei R, Otani S, Larson BJ, et al. Transport of cisplatin by the copper efflux transporter ATP7B [J]. Mol Pharmacol, 2008, 73(2): 461-468.
[18] Samimi G, Safaei R, Katano K, et al. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells [J]. Clin Cancer Res, 2004, 10(14): 4661-4669.
[19] Fukushima-Uesaka H, Saito Y, Maekawa K, et al. Genetic polymorphisms of copper- and platinum drug-efflux transporters ATP7A and ATP7B in Japanese cancer patients [J]. Drug Metab Pharmacokinet, 2009, 24(6): 565-574.
[20] Hah SS, Stivers KM, de Vere White RW, et al. Kinetics of carboplatin-DNA binding in genomic DNA and bladder cancer cells as determined by accelerator mass spectrometry [J]. Chem Res Toxicol, 2006, 19(5): 622-626.
[21] Giachino DF, Ghio P, Regazzoni S, et al. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer [J]. Clin Cancer Res, 2007, 13(10): 2876- 2881.
[22] Marsh S, Paul J, King CR, et al. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer [J]. J Clin Oncol, 2007, 25(29): 4528-4535.
[23] Ginsberg G, Angle K, Guyton K, et al. Polymorphism in the DNA repair enzyme XRCC1: utility of current database and implications for human health risk assessment [J]. Mutat Res, 2011, 727(1/2): 1-15.
[24] Stern MC, Umbach DM, van Gils CH, et al. DNA repair gene XRCC1 polymorphisms, smoking, and bladder cancer risk [J]. Cancer Epidemiol Biomarkers Prev, 2001, 10(2): 125-131.
[25] Kubota Y, Nash RA, Klungland A, et al. Reconstitution of DNA base excision-repair with purified human proteins: interaction between DNA polymerase beta and the XRCC1 protein [J]. EMBO J, 1996, 15(23): 6662-6670.
[26] Li Y, Huang XE, Jin GF, et al. Lack of any relationship between chemotherapy toxicity in non-small cell lung cancer cases and polymorphisms in XRCC1 codon 399 or XPD codon 751 [J]. Asian Pac J Cancer Prev, 2011, 12(3): 739-742.
[27] Pegg AE. Multifaceted roles of alkyltransferase and related proteins in DNA repair, DNA damage, resistance to chemotherapy, and research tools [J]. Chem Res Toxicol, 2011, 24(5): 618-639.
[28] 赵钢涛,杨凡,丁媛媛,等. 基因单核苷酸多态性对非小细胞肺癌铂类化疗敏感性影响的研究进展 [J]. 中国临床药理学与治疗学, 2010, 15(6): 715-719.
[29] Kang S, Ju W, Kim JW, et al. Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer [J]. Exp Mol Med, 2006, 38(3): 320-324.